In CRC with KRAS G12C, 115 (25.7%) had TMB ≥ 35, 103 (23%) had TMB ≥ 50, 93 (20.8%) had TMB ≥ 75, and 65 (14.5%) had TMB ≥ 100. This evidence concerns the gene KRAS and colorectal carcinoma.